<DOC>
	<DOCNO>NCT02610777</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pevonedistat plus azacitidine versus single-agent azacitidine participant higher-risk myelodysplastic syndrome , chronic myelomonocytic leukemia low-blast acute myelogenous leukemia .</brief_summary>
	<brief_title>An Efficacy Safety Study Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine Participants With Higher-Risk Myelodysplastic Syndromes ( HR MDS ) , Chronic Myelomonocytic Leukemia ( CMML ) Low-Blast Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>The drug test study call pevonedistat . Pevonedistat test treat people myelodysplastic syndrome , chronic myelomonocytic leukemia low-blast acute myelogenous leukemia combination treatment azacitidine . This study look overall survival , event free survival response treatment people take pevonedistat azacitidine compare people take single-agent azacitidine . The study enroll approximately 117 participant . Once enrol , participant randomly assign ( chance , like flip coin ) one two treatment group 28-day treatment cycle : - Pevonedistat 20 mg/m^2 azacitidine 75 mg/m^2 combination - Single-agent azacitidine 75 mg/m^2 All participant receive azacitidine via intravenous subcutaneous route . Participants randomized combination arm also receive pevonedistat intravenous infusion . This multi-center trial conduct worldwide . The overall time participate study approximately 69 month . Participants attend end-of-treatment visit 30 day last dose study drug start subsequent anti-neoplastic therapy occur sooner . Participants enter event-free survival follow-up ( study visit every 3 month ) disease transform AML ( participant HR MDS CMML ) progress ( participant low-blast AML ) , start subsequent therapy . Participants also enter overall survival follow-up ( contact every 3 month document subsequent therapy survival status ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Male female participant 18 year old . 2 . Morphologically confirm diagnosis MDS nonproliferative CMML ( , white blood cell [ WBC ] &lt; 20,000 per microliter [ /mcL ] ) lowblast AML base 1 follow : FrenchAmericanBritish ( FAB ) Classifications : Refractory anemia excess blast ( RAEB ) define 5 % 20 % myeloblast bone marrow . CMML 10 % 19 % myeloblast bone marrow and/or 5 % 19 % blast blood . OR Worl health organisation ( WHO ) Classifications : RAEB1 define 5 % 9 % myeloblast bone marrow . RAEB2 define 10 % 19 % myeloblast bone marrow and/or 5 % 19 % blast blood . CMML2 define 10 % 19 % myeloblast bone marrow and/or 5 % 19 % blast blood . CMML1 ( Although CMML1 define &lt; 10 % myeloblast bone marrow and/or &lt; 5 % blast blood , participant may enroll bone marrow blast &gt; =5 % . WHOdefined AML 20 % 30 % myeloblast bone marrow &lt; 30 % myeloblast peripheral blood deem investigator appropriate azacitidinebased therapy . 3 . For MDS CMML participant , prognostic risk category , base Revised International Prognostic Scoring System ( IPSSR ) , : Very high ( &gt; 6 point ) , High ( &gt; 4.5 6 point ) , Intermediate ( &gt; 3 4.5 point ) : participant determine Intermediate Prognostic Risk Category allowable set &gt; =5 % bone marrow myeloblast . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 5 . Clinical laboratory value within follow parameter ( repeat within 3 day first dose study drug laboratory value use randomization obtain 3 day first dose study drug ) : Albumin &gt; 2.7 g/dL . Total bilirubin &lt; upper limit normal ( ULN ) except participant Gilbert 's syndrome . Participants Gilbert 's syndrome may enroll direct bilirubin &lt; =1.5*ULN direct bilirubin . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5*ULN . Creatinine clearance &gt; =50 milliliter per minute ( mL/min ) . Hemoglobin &gt; 8 g/dL . Participants may transfuse achieve value . Elevated indirect bilirubin due posttransfusion hemolysis allow . 6 . For CMML participant : WBC count &lt; 20,000/mcL administration first dose study drug Cycle 1 Day 1 ; participant must hydroxyurea least 1 week prior WBC count assessment . 7 . Ability undergo studyrequired bone marrow sample collection procedure . 8 . Suitable venous access studyrequired blood sampling ( , include pharmacokinetic ( PK ) biomarker sample ) . 9 . Female participant : Are postmenopausal least 1 year Screening visit , Are surgically sterile , If childbearing potential , agree practice 1 highly effective method 1 additional effective ( barrier ) method contraception time , time signing inform consent 4 month last dose study drug , Agree practice true abstinence , line prefer usual lifestyle participant . ( Periodic abstinence [ example , calendar , ovulation , symptothermal , postovulation method ] withdrawal , spermicide , lactational amenorrhea acceptable method contraception . Female male condom use together ) . Male participant , even surgically sterilize ( , status postvasectomy ) , : Agree practice effective barrier contraception entire study treatment period 4 month last dose study drug , Agree practice true abstinence , line prefer usual lifestyle participant . ( Periodic abstinence [ example , calendar , ovulation , symptothermal , postovulation method female partner ] withdrawal , spermicide , lactational amenorrhea acceptable method contraception . Female male condom use together ) . 10 . Voluntary write consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw participant time without prejudice future medical care . 1 . Previous treatment decitabine azacitidine hypomethylating agent . 2 . Acute promyelocytic leukemia diagnose morphologic examination bone marrow , fluorescent situ hybridization cytogenetics peripheral blood bone marrow , accept analysis . 3 . Eligible allogenic stem cell transplantation . 4 . Participants MDS , CMML , lowblast AML , whose site disease extramedullary , example , skin . 5 . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion study procedure could limit participant expect survival le 6 month . 6 . Treatment antileukemic/antiMDS therapy ( eg , lenalidomide , cytarabine , anthracyclines , purine analog ) investigational product within 14 day first dose study drug . 7 . Known hypersensitivity mannitol . 8 . Active uncontrolled infection severe infectious disease , severe pneumonia , meningitis , septicemia . 9 . Major surgery within 14 day first dose schedule surgery study period ; insertion venous access device ( eg , catheter , port ) consider major surgery . 10 . Diagnosed treat another malignancy within 2 year randomization previously diagnose another malignancy evidence residual disease . Participants nonmelanoma skin cancer carcinoma situ type exclude undergone resection . 11 . Lifethreatening illness unrelated cancer . 12 . Prothrombin time ( PT ) prolongation activate thromboplastin time ( aPTT ) &gt; 1.5 ULN active uncontrolled coagulopathy bleeding disorder . 13 . Known human immunodeficiency virus ( HIV ) seropositive . 14 . Known hepatitis B surface antigen seropositive , know suspect active hepatitis C infection . Note : Participants isolate positive hepatitis B core antibody ( , set negative hepatitis B surface antigen negative hepatitis B surface antibody ) must undetectable hepatitis B viral load . 15 . Known hepatic cirrhosis severe preexist hepatic impairment . 16 . Known cardiopulmonary disease define unstable angina , clinically significant arrhythmia , congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) and/or myocardial infarction within 6 month prior first dose , severe pulmonary hypertension . As example , wellcontrolled atrial fibrillation would exclusion whereas uncontrolled atrial fibrillation would exclusion . 17 . Treatment strong cytochrome P450 ( CYP ) 3A inhibitor inducer within 14 day first dose study drug . 18 . Systemic antineoplastic therapy radiotherapy malignant condition within 12 month first dose study drug , except hydroxyurea . 19 . Female participant lactate breast feed positive serum pregnancy test Screening period positive urine pregnancy test Day 1 first dose study drug . 20 . Female participant intend donate egg ( ovum ) course study 4 month receive last dose study drug ( ) . 21 . Male participant intend donate sperm course study 4 month receive last dose study drug ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>